These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35006035)

  • 1. Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease.
    Morrison JT; Govsyeyev N; Hess CN; Bonaca MP
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484211056115. PubMed ID: 35006035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).
    Bonaca MP; Gutierrez JA; Creager MA; Scirica BM; Olin J; Murphy SA; Braunwald E; Morrow DA
    Circulation; 2016 Mar; 133(10):997-1005. PubMed ID: 26826179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial.
    Qamar A; Morrow DA; Creager MA; Scirica BM; Olin JW; Beckman JA; Murphy SA; Bonaca MP
    Vasc Med; 2020 Apr; 25(2):124-132. PubMed ID: 32000630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial.
    Bonaca MP; Creager MA; Olin J; Scirica BM; Gilchrist IC; Murphy SA; Goodrich EL; Braunwald E; Morrow DA
    JACC Cardiovasc Interv; 2016 Oct; 9(20):2157-2164. PubMed ID: 27765312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.
    Lam S; Tran T
    Cardiol Rev; 2015; 23(5):261-7. PubMed ID: 25923910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial.
    Gilchrist IC; Morrow DA; Creager MA; Olin JW; Scirica BM; Goodrich EL; Bonaca MP
    J Am Heart Assoc; 2021 Oct; 10(20):e021412. PubMed ID: 34622665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
    Arif SA; D'Souza J; Gil M; Gim S
    Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of vorapaxar as approved for clinical use in the United States.
    Magnani G; Bonaca MP; Braunwald E; Dalby AJ; Fox KA; Murphy SA; Nicolau JC; Oude Ophuis T; Scirica BM; Spinar J; Theroux P; Morrow DA
    J Am Heart Assoc; 2015 Mar; 4(3):e001505. PubMed ID: 25792124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
    Moon JY; Franchi F; Rollini F; Angiolillo DJ
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):23-37. PubMed ID: 28565918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vorapaxar in the secondary prevention of atherothrombotic events.
    Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
    N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
    Bonaca MP; Scirica BM; Creager MA; Olin J; Bounameaux H; Dellborg M; Lamp JM; Murphy SA; Braunwald E; Morrow DA
    Circulation; 2013 Apr; 127(14):1522-9, 1529e1-6. PubMed ID: 23501976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of vorapaxar for the prevention of atherothrombotic events.
    Wang A
    Expert Opin Pharmacother; 2015; 16(16):2509-22. PubMed ID: 26480240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vorapaxar: first global approval.
    Poole RM; Elkinson S
    Drugs; 2014 Jul; 74(10):1153-63. PubMed ID: 24962425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vorapaxar in atherosclerotic disease management.
    Cheng JW; Colucci V; Howard PA; Nappi JM; Spinler SA
    Ann Pharmacother; 2015 May; 49(5):599-606. PubMed ID: 25680760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50.
    Kidd SK; Bonaca MP; Braunwald E; De Ferrari GM; Lewis BS; Merlini PA; Murphy SA; Scirica BM; White HD; Morrow DA
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27431644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.
    Gryka RJ; Buckley LF; Anderson SM
    Drugs R D; 2017 Mar; 17(1):65-72. PubMed ID: 28063023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary Medical Management of Peripheral Artery Disease.
    Bonaca MP; Hamburg NM; Creager MA
    Circ Res; 2021 Jun; 128(12):1868-1884. PubMed ID: 34110910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
    Bohula EA; Bonaca MP; Braunwald E; Aylward PE; Corbalan R; De Ferrari GM; He P; Lewis BS; Merlini PA; Murphy SA; Sabatine MS; Scirica BM; Morrow DA
    Circulation; 2016 Jul; 134(4):304-13. PubMed ID: 27440003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).
    Jones WS; Tricoci P; Huang Z; Moliterno DJ; Harrington RA; Sinnaeve PR; Strony J; Van de Werf F; White HD; Held C; Armstrong PW; Aylward PE; Chen E; Patel MR; Mahaffey KW
    Am Heart J; 2014 Oct; 168(4):588-96. PubMed ID: 25262270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
    Cheng JW
    Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.